was used in 123 patients, and the suboccipital transcerebellar approach was used in the remaining 19. All biopsy specimens were formalin-fixed and analyzed after staining with H & E, Masson trichrome, and immunostains. The procedure was considered successful in cases in which a definitive diagnosis was obtained and confirmed by the clinical course of the tumor.
The overall diagnosis rate of the biopsy procedure was 93.7%, and in 9 patients the biopsy results were negative. Diffuse brainstem glioma was diagnosed in 100 patients. Other neoplastic diseases were diagnosed in 23 patients. Moreover, histological evaluation revealed nonneoplastic lesions in 10 patients ( Table 1 ). The tumors were graded according to WHO classification; low-grade gliomas were classified as Grade II and high-grade gliomas as Grades III and IV. 10 Of the patients with diffuse brainstem glioma, 63 were adults, including 40 men and 23 women who ranged in age from 18 to 75 years (mean 41 years). Thirty-seven patients were children, including 19 boys and 18 girls who ranged in age from 2 to 12 years (mean 6.9 years). Patient follow-up occurred from 4 days to 278 months after the biopsy (mean 40.4 months).
Eighty-four patients received conventional focal radiotherapy; 9 patients were not treated because they presented with minor symptoms, nonprogressive tumors, and a histological diagnosis of low-grade glioma; and 7 patients died before radiotherapy was performed. Chemotherapy was administered to 40 patients at the time of relapse or when radiotherapy failed.
Regarding complications in the current series, 1 death occurred due to the procedure and 13 patients (9.8%) presented with definitive complications.
Statistical Analysis
Data analysis was performed using Epi info (version 6.02, Centers for Disease Control) and MedCalc (version 9.3.0.9, bvba). Univariate analysis of the following variables was performed: characteristics of T1-weighted MRI studies after infusion of Gd, histological grade, and patient age.
Survival time was measured from the time of the biopsy procedure to the date of the patient's last follow-up or death due to diffuse glioma. Survival was estimated using the Kaplan-Meier method with 95% confidence intervals. Comparison of Kaplan-Meier curves between histological grades (low-grade vs high-grade glioma), characteristics of T1-weighted MRI after infusion of Gd (enhancing vs nonenhancing tumors), and age (adults vs children) were performed using the log-rank test. The Cox proportional hazards model was used to test prognostic factors in multivariate analysis. Parameters were considered statistically significant at a value of p < 0.05.
Results
The histological grade of the diffuse high-grade gliomas was determined in 51 patients (51%; 32 adults and 19 children). Diffuse low-grade gliomas were diagnosed in 49 patients (31 adults and 18 children). At the time of the last follow-up in August 2007, 55 patients (55%) had died.
The mean overall survival of this population, measured from the date of biopsy, was 57 months for diffuse low-grade glioma and 13.8 months for diffuse high-grade glioma (p < 0.001). A comparison between the KaplanMeier survival curves for adults and children revealed a similar median survival period of 25 and 16 months, respectively (p > 0.05). The 1-year actuarial survival for adults was 64% ± 0.6% and for children it was 66% ± 0.08% (p > 0.05) (Fig. 1) . Figure 2 shows the comparison of Kaplan-Meier survival of the 2 subgroups of diffuse glioma. The 1-year actuarial survival rates for patients classified with lowgrade and high-grade gliomas were 87.6% ± 0.04% and 34.9% ± 0.8%, respectively (Fig. 3) .
In the patients with low-grade glioma, the 1-year survival rates were 92.9% for adults and 79.4% for children (p = 0.07). In the high-grade glioma group, the 1-year survival rates were 29.1% for adults and 44.9% for children (p = 0.34). These differences were not statically significant.
In the group of adults, the comparison of KaplanMeier curve survival showed higher survival in patients with low-grade glioma. The 1-year actuarial survival rates for adult patients were 92.9% for low-grade gliomas and 29.1% for high-grade gliomas. This difference was statistically significant (p = 0.0001) (Fig. 4) . However, in the group of children, the 1-year actuarial survival rates for patients classified as harboring low-and high-grade gliomas were 80.4% ± 0.08% and 48.6% ± 0.14%, respectively. This difference was not statistically significant (p = 0.0755) (Fig. 5) .
Regarding MRI characteristics, 51 patients (29 adults and 22 children) presented with contrast-enhancing lesions. Nonenhancing lesions were observed in 48 patients (34 adults and 14 children). One patient had a T1-weighted image without Gd infusion.
The mean survival among patients with nonenhancing lesions on MRI was 54.2 months, whereas that for pa- tients with enhancing lesions was 21.7 months (p < 0.001).
The Kaplan-Meier curve also revealed greater survival for patients with nonenhancing tumors (Fig. 6) ; moreover, the 1-year actuarial survival rate for patients with nonenhancing tumors was 88.6% ± 0.04%, while for enhancing tumors, it was 44.9% ± 0.07% (Fig. 7) . Multivariate analysis (Cox proportional hazards regression) revealed that only histological grade (p = 0.001) was a significant prognostic factor. The variables MRI findings (p = 0.053) and age (p = 0.27) had no statistically significant relation to patient survival in this analysis.
Discussion
In most studies, treatment decisions for brainstem glioma are based on MRI features alone and do not include histopathological diagnosis. Most authors regard biopsy procedures for intrinsic brainstem tumors as being too dangerous and consider imaging methods as sufficiently reliable. 1, 5 Thus, the impact of MRI findings on treatment decisions for brainstem tumors is very high, but the accuracy of MRI-based diagnosis of diffuse brainstem gliomas has not been fully verified by histopathological findings. 8 Thus, some authors have reported that all diffuse brainstem gliomas located above the medulla behave as high-grade astrocytomas, and histological grade is not a significant factor for the survival of these patients. 1, 4, 5, 18, 20 Few studies have been conducted concerning prognosis and prognostic factors in brainstem gliomas. 1 This may be due to the low incidence of these tumors and the fact that histopathological diagnosis is rarely confirmed.
The present study showed that of the 3 factors studied, in univariate analysis, contrast enhancement and histological grade were significant prognostic factors, but age was not. In multivariate analysis, only histological grade remained a significant prognostic factor. However, the histological grade was a significant prognostic factor only in the group of adults. In children, despite the longer survival of patients with low-grade glioma, the difference was not statistically significant (p = 0.088).
These data are similar to those published by Selvapandian et al., 17 who demonstrated that the tumor grade was a significant factor in predicting survival in adults, but in children it did not correlate with outcome. However, Broniscer et al. 3 showed improved outcome in children who are younger than 3 years.
Rachinger et al. 14 recently reported that adult patients with diffuse low-grade gliomas showed a 1-year survival rate of 93%, while this rate was 42% in patients with diffuse high-grade gliomas, also demonstrating the impact of histological grade on the survival of these patients.
Using univariate analysis, Guillamo et al. 6 showed in adults with diffuse glioma that histological grade and MRI "necrosis" were significant prognostic factors but that contrast enhancement not. When histological grade and MRI necrosis were included in multivariate analysis, the relative risks of these factors were similar, but only MRI necrosis was considered significant. It is highly probable that conventional fractionated radiotherapy will not remain the only efficient treatment in diffuse brainstem glioma over the next few decades. In addition, for patients with low-grade gliomas, an initial observational policy is being adopted, followed by treatment when the patient's disease progresses clinically. 17 Indeed, new chemotherapies, gene therapies, or immunotherapies, alone or in combination, will certainly succeed in improving the outcome of these patients. 6, 16, 19 These therapies will undoubtedly require tissue sampling for diagnostic confirmation and histological grade, for molecular marker studies, or for immunological purposes prior to adopting target therapies. 16 Therefore, Pollack et al. 13 found that overexpression of p53 in malignant gliomas during childhood is strongly associated with adverse outcome, independent of clinical prognostic and histological findings.
Conclusions
This study revealed that histological grade and MRI features were significant prognostic factors for survival in these patients, but in multivariate analysis only histological grade remained a significant factor. Further studies should be conducted to determine whether histological grade has a greater impact than MRI alone on the treatment of these patients.
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